DUBLIN--(BUSINESS WIRE)--The "Sinusitis - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Sinusitis - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Sinusitis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A detailed picture of the Sinusitis pipeline landscape is provided which includes the disease overview and Sinusitis treatment guidelines. The assessment part of the report embraces, in depth Sinusitis commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Sinusitis.
- In the coming years, the Sinusitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Sinusitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Sinusitis treatment market. Several potential therapies for Sinusitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Sinusitis market size in the coming years.
- This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Sinusitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Sinusitis Emerging Drugs Chapters
This segment of the Sinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sinusitis Emerging DrugsGLS-1200: GeneOne Life Science
GLS-1200 nasal spray stimulates multiple bitter taste receptors (TAS2Rs) on ciliated nasal epithelial cells to produce nitric oxide as part of the innate immune system. Nitric oxide has generalized anti-microbial activity in the upper respiratory tract. Currently, it is in Phase II stage of clinical trial evaluation to treat chronic Sinusitis.
LYR-210: Lyra Therapeutics
Lyra's lead product candidate, LYR-210, to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra's XTreoT platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of surgically-naive CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients. Currently, it is in Phase III stage of clinical trial evaluation to treat chronic rhinosinusitis.
TRL 1068: TRELLIS BIOSCIENCE
Trellis Bioscience has used its CellSpot Technology to identify a high-affinity and broad-spectrum native human antibody, TRL1068, which targets and disintegrates bacterial biofilm. Biofilm is a physiological factor promoting drug resistance in most clinically relevant multi-drug-resistant bacteria species, both gram positive and gram negative. Biofilm is also implicated as a factor promoting Alzheimer's pathogenesis. Currently, it is in Phase I stage of clinical trial evaluation to treat Chronic Rhinosinusitis with Nasal Polyps.
Sinusitis: Therapeutic Assessment
This segment of the report provides insights about the different Sinusitis drugs segregated based on following parameters that define the scope of the report.
Major Players in Sinusitis
There are approx. 15+ key companies which are developing the therapies for Sinusitis. The companies which have their Sinusitis drug candidates in the most advanced stage, i.e. phase III include, Lyra Therapeutics.
PhasesThe report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Sinusitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sinusitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sinusitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sinusitis drugs.
Sinusitis Report Insights
- Sinusitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Sinusitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- GeneOne Life Science
- Lyra Therapeutics
- TRELLIS BIOSCIENCE
- Sanotize Research and Development
- Sanofi
- OptiNose
- Biohaven Pharmaceuticals
- Keymed Biosciences Co.Ltd
- Suzhou Connect Biopharmaceuticals, Ltd.
- Genentech, Inc.
- Pfizer
- BEAM Alliance
- Insmed Incorporated
- Lanier Biotherapeutics
- GlycoMira
- IVIEW Therapeutics Inc.
- Nota Laboratories LLC
- Quorum Innovations
Key Products
- GLS-1200
- LYR-210
- TRL 1068
- Nitric Oxide
- Qi-301
- GM-1111
- Dupilumab
- IVIEW-1501/1502
- OPN-375
- VXD-005
- Brensocatib
- Rimegepant
- CM326
- CM310
- CBP-201
- Omalizumab
- PF-06817024
- LNR 125.38
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/v90ygq
